ArticleCancer cell2015

CHZ868, a Type II JAK2 Inhibitor, Reverses Type I JAK Inhibitor Persistence and Demonstrates Efficacy in Myeloproliferative Neoplasms.

Sara C Meyer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.